Core Viewpoint - The company, Shantou Ultrasonic Instrument Research Institute Co., Ltd., has shown significant growth in its stock performance and is benefiting from various market trends, including the pet economy and medical device sector, as well as the depreciation of the RMB [1][2]. Company Overview - Shantou Ultrasonic Instrument Research Institute Co., Ltd. specializes in the research, production, and sales of medical imaging equipment and industrial non-destructive testing equipment, with a focus on ultrasound technology [2][3]. - The company was established on November 15, 1982, and went public on January 22, 2025 [7]. - The main revenue sources for the company are medical ultrasound (71.16%), industrial ultrasound (17.30%), accessories (5.72%), X-ray (4.56%), and other (1.26%) [7]. Financial Performance - For the period from January to September 2025, the company reported a revenue of 254 million yuan, a year-on-year decrease of 2.90%, and a net profit attributable to shareholders of 88.94 million yuan, down 3.66% year-on-year [7][8]. - As of September 30, 2025, the company had a total market capitalization of 10.151 billion yuan [1]. Market Position and Trends - The company has a significant overseas revenue share of 55.26%, benefiting from the depreciation of the RMB [3]. - The stock has experienced a recent increase of 5.15% in value, with a trading volume of 166 million yuan and a turnover rate of 12.02% [1]. Shareholder Information - As of September 30, 2025, the number of shareholders decreased by 23.90% to 17,000, while the average number of circulating shares per person increased by 39.99% to 3,438 shares [7]. - The largest shareholder is Huabao Zhongzheng Medical ETF, holding 1.5245 million shares, which is a decrease of 388,200 shares compared to the previous period [9].
超研股份涨5.15%，成交额1.66亿元，今日主力净流入1242.75万